CNTA vs. LEGN, GRFS, TLX, TGTX, LNTH, NUVL, AXSM, AKRO, PCVX, and ADMA
Should you be buying Centessa Pharmaceuticals stock or one of its competitors? The main competitors of Centessa Pharmaceuticals include Legend Biotech (LEGN), Grifols (GRFS), Telix Pharmaceuticals (TLX), TG Therapeutics (TGTX), Lantheus (LNTH), Nuvalent (NUVL), Axsome Therapeutics (AXSM), Akero Therapeutics (AKRO), Vaxcyte (PCVX), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry.
Centessa Pharmaceuticals vs. Its Competitors
Legend Biotech (NASDAQ:LEGN) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.
70.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by insiders. Comparatively, 7.1% of Centessa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Legend Biotech has higher revenue and earnings than Centessa Pharmaceuticals. Legend Biotech is trading at a lower price-to-earnings ratio than Centessa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Legend Biotech presently has a consensus price target of $72.60, suggesting a potential upside of 105.37%. Centessa Pharmaceuticals has a consensus price target of $27.89, suggesting a potential upside of 94.55%. Given Legend Biotech's higher probable upside, research analysts plainly believe Legend Biotech is more favorable than Centessa Pharmaceuticals.
Legend Biotech has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500. Comparatively, Centessa Pharmaceuticals has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500.
In the previous week, Legend Biotech had 6 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 8 mentions for Legend Biotech and 2 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 0.86 beat Legend Biotech's score of 0.59 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media.
Centessa Pharmaceuticals has a net margin of 0.00% compared to Legend Biotech's net margin of -29.95%. Legend Biotech's return on equity of -21.19% beat Centessa Pharmaceuticals' return on equity.
Summary
Centessa Pharmaceuticals beats Legend Biotech on 8 of the 15 factors compared between the two stocks.
Get Centessa Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNTA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Centessa Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:CNTA) was last updated on 7/4/2025 by MarketBeat.com Staff
